Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today announced a plan to invest an additional approximately €500 million to expand capacity at the company's smoke-free product manufacturing facility in Crespellano (Bologna, Italy). The facility at Crespellano is PMI's first dedicated manufacturing facility for large scale production of HEETS, the tobacco units used with the electronic tobacco heating device IQOS. Completed in September 2016, the facility currently employs over 600 people with a high level of technical expertise in areas such as mechanical engineering electronics and chemistry. The expansion is expected to be completed by the end of 2018 and is part of the company's plans to have a total annual installed capacity of approximately 100 billion heated tobacco units by the end of next year. " Last week, we announced our second greenfield facility in Dresden (Germany). The expansion of our first one, in Crespellano, shows the momentum of our efforts to turn PMI's vision for a smoke-free future into a reality as soon as possible," said Frederic de Wilde, President of PMI's European Union Region. Michele Cattoni, PMI's VP Technology & Operations RRPs, added: " The opening of the Crespellano plant represented a historic milestone in PMI's commitment to replace cigarettes with better alternatives to the benefit of smokers, public health and society at large. We are now rapidly expanding our capacity to manufacture smoke-free products in order to meet growing demand from adult smokers." IQOS and HEETS were first made available for adult smokers in Milan in November 2014. IQOS is currently available nationwide in Italy, and in key cities or nationwide in more than 25 markets around the world. More than two million people have already given up smoking and switched to IQOS. The expansion of the Bologna facility follows the announcement earlier this month that PMI will invest approximately USD 320 million in a HEETS production facility in Dresden, Germany, adding to the previously announced investments in the conversion of cigarette manufacturing facilities in Greece, Romania and Russia to HEETS production. IQOS is one of four scientifically substantiated smoke-free product platforms that PMI is developing to address adult smoker demand for better alternatives to cigarettes. Since 2008, PMI has hired more than 400 scientists and experts and invested over USD 3 billion in research, product development and scientific substantiation for smoke-free products. The company openly shares its scientific methodologies and findings for independent third-party review and verification, and has published its research in over 200 articles and book chapters since 2011. Results of scientific research conducted by PMI to date indicate that switching completely to IQOS is likely to reduce the risk of harm compared to cigarette smoking, and is a better choice for those who would otherwise continue to smoke. Philip Morris International Inc. Philip Morris International Inc. (PMI) is the world's leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of reduced-risk products (RRPs). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.